Latest News and Press Releases
Want to stay updated on the latest news?
-
Conference call to be held on Monday, May 11, 2015 at 5:00 p.m. Eastern Time - Positive momentum on clinical trials and research continues - Multiple strategic transactions...
-
Transaction Provides Transformative Cell Selection and Activation Capabilities, Advanced Manufacturing Automation, Improved Supply Chain, and Lower Expected Cost of Goods Initial Payment of...
-
SEATTLE, May 6, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (Nasdaq:JUNO) today announced that it will webcast its presentation at the Bank of America Merrill Lynch 2015 Health Care Conference at...
-
SEATTLE, May 5, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (Nasdaq:JUNO) will announce financial results for the first quarter of 2015 on Monday, May 11, 2015 after the close of U.S.-based...
-
GAITHERSBURG, Md. and SEATTLE, April 23, 2015 (GLOBE NEWSWIRE) -- MedImmune, the global biologics research and development arm of AstraZeneca, and Juno Therapeutics, Inc., a biopharmaceutical company...
-
SEATTLE, April 21, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (Nasdaq:JUNO), a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer,...
-
SEATTLE, April 6, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (Nasdaq:JUNO) today announced that it entered into a settlement agreement to resolve litigation with the Trustees of the University...
-
Conference call to be held on Wednesday, March 18, 2015 at 5:00 p.m. Eastern Time Positive momentum and progress on clinical trials continues Strong year-end cash position of $474.1...
-
SEATTLE, March 11, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (Nasdaq:JUNO) will announce financial results for the fourth quarter and year ended December 31, 2014 on Wednesday, March 18, 2015...
-
SEATTLE, Feb. 24, 2015 (GLOBE NEWSWIRE) -- Juno Therapeutics, Inc. (Nasdaq:JUNO) today announced that it will webcast its presentations at the below listed investor conferences in March. Hans...